It's not often that a single clinical trial wipes out an entire
therapeutic opportunity, but that is what most sell-side analysts seem
to believe about Medtronic's (NYSE: MDT ) U.S. pivotal trial failure with its Symplicity renal denervation device. In the wake of Medtronic's surprising setback, both St. Jude Medical (NYSE: STJ ) and Boston Scientific (NYSE: BSX ) have hit "pause" on their renal denervation programs, while Covidien (NYSE: COV ) has chosen to tap out, ending development of its OneShot system altogether.
There may be life in the approach yet, though. Johnson & Johnson (NYSE: JNJ ) recently
announced that it received European approval (the CE Mark) for RENLANE
system, a multi-electrode RF ablation device that many people didn't
even know was in development. That begs the question of whether this
means there is opportunity yet in what was once touted as a
multibillion-dollar area.
Read the full article here:
Does This Johnson & Johnson Product Have Blockbuster Potential?
No comments:
Post a Comment